Holen Sie sich die Stockscreener-App
49.00
7.22%
3.30
Schlusskurs vom Vortag:
$45.70
Offen:
$48.93
24-Stunden-Volumen:
4.52M
Relative Volume:
2.83
Marktkapitalisierung:
$5.81B
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
26.06
EPS:
1.88
Netto-Cashflow:
$392.71M
1W Leistung:
+7.34%
1M Leistung:
-4.95%
6M Leistung:
+7.74%
1J Leistung:
+22.16%
1-Tages-Spanne:
$46.21
$49.57
1-Wochen-Bereich:
$42.01
$49.57
52-Wochen-Spanne:
$33.15
$65.53
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Vergleichen Sie HALO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| HALO | 49.00 | 5.81B | 947.36M | 392.47M | 392.71M | 1.88 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
San Diego’s Halozyme withdraws $2.1B Evotec bid, just one week after making offer - The San Diego Union-Tribune
Halozyme Withdraws Proposal To Buy Evotec, Citing ‘Unwillingness To Engage’ - Scrip
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why - MSN
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook - AOL
Halozyme Pulls €2B Bid After Evotec Fails To Engage In Talks - Law360
Halozyme withdraws $2.1 bln buyout offer for German drug developer Evotec - Reuters.com
Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal - MSN
Evotec SE (EVO) Comment on Withdrawn Non-Binding Offer from Halozyme (HALO) - StreetInsider.com
Evotec takes notice of Halozyme withdrawal, convicted in standalone strategy - TipRanks
Halozyme ends bid to acquire Evotec at €2 billion valuation - Investing.com India
Evotec plummetsHalozyme withdraws purchase bid - Marketscreener.com
Halozyme withdraws $2.1 billion buyout offer for Evotec - MSN
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - Yahoo Finance
Halozyme Withdraws Bid For Evotec - Contract Pharma
Halozyme stock gains after pulling Evotec bid (HALO:NASDAQ) - Seeking Alpha
Halozyme Withdraws Bid to Purchase Drug Developer Evotec - Bloomberg
Halozyme ends bid to acquire Evotec at €2 billion valuation By Investing.com - Investing.com UK
Halozyme Withdraws €2B Evotec Bid, Maintains Strong $1B Revenue Outlook | EVO Stock News - StockTitan
Halozyme eyes continuous manufacturing platform in $2.1bn Evotec bid - BioProcess Insider
B. Metzler seel. Sohn & Co. Holding AG Invests $1.90 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial - Yahoo Finance
Thrivent Financial for Lutherans Lowers Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Natixis Advisors LLC - MarketBeat
It has been confirmed that Merck (MSD), a large global pharmaceutical company, has filed a patent in.. - 매일경제
San Diego biotech Halozyme makes $2.1B bid for German drugmaker - The San Diego Union-Tribune
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Aurora Investment Counsel Sells 12,753 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Segall Bryant & Hamill LLC Has $20.33 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery - MSN
Breaking Down Halozyme Therapeutics: 10 Analysts Share Their Views - Benzinga
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - MSN
Evotec jumps on report Halozyme expressed takeover interest - MSN
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) - MSN
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal - Seeking Alpha
Halozyme Therapeutics (NASDAQ:HALO) Shares Gap UpHere's Why - MarketBeat
Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now? - Yahoo Finance
Are Medical Stocks Lagging Cencora, Inc. (COR) This Year? - Yahoo Finance
Evotec weakPossible defense battle dampens takeover fantasy - Marketscreener.com
Victory Capital Management Inc. Has $23.29 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme CEO: Evotec Is Poised for Growth - Marketscreener.com
Halozyme outlines plan to acquire Evotec for €2 billion - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Halozyme Bids €2B for Evotec, Eyes $2B Revenue by 2025 in Pharma Services Push | EVO Stock News - StockTitan
Royce & Associates LP Decreases Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme (HALO) Eyes $21 Billion Cash Acquisition of Evotec (EVO) - GuruFocus.com
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - Yahoo Finance
The week in pharma: action, reaction and insight – week to November 15 - The Pharma Letter
Cornercap Investment Counsel Inc. Sells 20,204 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
South Street Advisors LLC Purchases New Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Mizuho Markets Americas LLC Trims Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):